Erwin Dreesen
YOU?
Author Swipe
View article: High Doses of Antidepressants and Long-term Treatment of Obsessive-compulsive Disorder: Another Barrier to Accessing Deep Brain Stimulation?
High Doses of Antidepressants and Long-term Treatment of Obsessive-compulsive Disorder: Another Barrier to Accessing Deep Brain Stimulation? Open
View article: A Multiple Imputation Workflow for Handling Missing Covariate Data in Pharmacometrics Modeling
A Multiple Imputation Workflow for Handling Missing Covariate Data in Pharmacometrics Modeling Open
Covariate missingness is a prevalent issue in pharmacometrics modeling. Incorrect handling of missing covariates can lead to biased parameter estimates, adversely affecting clinical practice and drug development dosing decisions. Single im…
View article: Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease
Ustekinumab Drug Clearance Is Better Associated with Disease Control than Serum Trough Concentrations in a Prospective Cohort of Inflammatory Bowel Disease Open
Background/Objectives: This study aimed to compare the association of ustekinumab (UST) drug clearance (CL) and trough drug concentrations with disease activity in patients with inflammatory bowel diseases (IBDs). Methods: A prospective co…
View article: Model-informed precision dosing in inflammatory bowel diseases
Model-informed precision dosing in inflammatory bowel diseases Open
View article: Human serum albumin: prediction model and reference values for preterm and term neonates
Human serum albumin: prediction model and reference values for preterm and term neonates Open
View article: Correction: Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools
Correction: Model-Informed Precision Dosing of Tacrolimus: A Systematic Review of Population Pharmacokinetic Models and a Benchmark Study of Software Tools Open
View article: Model-informed precision dosing: State of the art and future perspectives
Model-informed precision dosing: State of the art and future perspectives Open
View article: Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study Open
Background Biologics for psoriasis demonstrate varying clinical outcome in real‐world practice, implying potential under‐ and overexposure. Objectives In this prospective cohort study we aimed to develop and validate an in‐house sandwich‐t…
View article: <scp>Exposure–response</scp> relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis
<span>Exposure–response</span> relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis Open
Background Response to biologics in psoriasis varies in real‐world settings. Serum biomarkers could aid biologic selection and dose modifications to improve patient outcomes while encouraging cost‐effective care. Objectives To explore the …
View article: The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism
The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism Open
Purpose: Uterine serous carcinoma (USC) is generally associated with poor prognosis due to a high recurrence rate and frequent treatment resistance; hence, there is a need for improved therapeutic strategies. Molecular analysis of USC iden…
View article: Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole
Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole Open
View article: Do we perceive sensations inside and outside of our body differently? Perceptual, emotional, and behavioral differences between visceral and somatic sensation, discomfort, and pain
Do we perceive sensations inside and outside of our body differently? Perceptual, emotional, and behavioral differences between visceral and somatic sensation, discomfort, and pain Open
Background Experimental research evaluating differences between the visceral and somatic stimulation is limited to pain and typically uses different induction methods for visceral and somatic stimulation (e.g., rectal balloon distention vs…
View article: Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe
Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe Open
The European Cooperation in Science and Technology (COST) action ENOTTA (The European Network on Optimising Treatment with Therapeutic Antibodies in chronic inflammatory diseases) was launched in 2022. To pave the way for harmonization of …
View article: TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology
TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology Open
Transient receptor potential Ankyrin 1 (TRPA1) is an ion channel expressed by sensory neurons, where it mediates pain signaling. Consequently, it has emerged as a promising target for novel analgesics, yet, to date, no TRPA1 antagonists ha…
View article: Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates Open
The lethality of patients with ovarian cancer (OC) remains high. Current treatment strategies often do not lead to the desired outcome due to the development of therapy resistance, resulting in high relapse rates. Additionally, clinical tr…
View article: Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review
Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review Open
Effective dosing of isavuconazole in patients supported by extracorporeal membrane oxygenation (ECMO) is important due to the role of isavuconazole as a first-line treatment in patients with influenza- and COVID-19-associated pulmonary asp…
View article: P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis
P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis Open
Background Infliximab (IFX) is used to treat patients with acute severe ulcerative colitis (ASUC) who fail to respond to intravenous corticosteroid therapy. Yet, a significant proportion of patients does not respond adequately and requires…
View article: P374 Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a pharmacokinetic simulation study
P374 Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a pharmacokinetic simulation study Open
Background Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) were recently approved for maintenance treatment of patients with inflammatory bowel disease. However, further investigation is required to identify the pa…
View article: P181 infliximab exposure during induction associate with time to remission and disease control of inflammatory bowel disease
P181 infliximab exposure during induction associate with time to remission and disease control of inflammatory bowel disease Open
Background Infliximab (IFX) exposure is established predictive factor of pharmacokinetic (PK) origin in inflammatory bowel disease, and expert consensus is to achieve adequate exposure during induction (1). We evaluated the performance of …
View article: P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval
P701 A time-to-event model relating infliximab trough concentrations to the risk of relapse after extending the infusion interval Open
Background Extending the infliximab infusion interval has been attempted in patients with Crohn’s disease (CD) and ulcerative colitis (UC) who sustained treatment response following an earlier interval shortening. We aimed to identify pred…
View article: P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases
P531 A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseases Open
Background Adequate infliximab (IFX) concentrations during induction treatment are predictive for deep remission (corticosteroid-free clinical and endoscopic remission) at six months in children with Crohn’s disease (CD) and ulcerative col…
View article: Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults
Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults Open
We aimed to evaluate the predictive performance and predicted doses of a single-model approach or several multi-model approaches compared with the standard therapeutic drug monitoring (TDM)-based vancomycin dosing. We performed a hospital-…
View article: Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases Open
Infliximab dosage de‐escalation without prior knowledge of drug concentrations may put patients at risk for underexposure and trigger the loss of response. A single‐model approach for model‐informed precision dosing during infliximab maint…
View article: Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders Open
Serum albumin (SA), the most abundant soluble protein in the body, maintains plasma oncotic pressure and regulates the distribution of vascular fluid and has a range of other important functions. The goals of this review are to expand clin…
View article: Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice
Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice Open
EDITORIAL article Front. Pharmacol., 24 May 2022Sec. Obstetric and Pediatric Pharmacology https://doi.org/10.3389/fphar.2022.931843
View article: Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA‐FLU study
Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA‐FLU study Open
Background Data on posaconazole in the critically ill are scarce. In the POSA‐FLU study, we examined the prevention of influenza‐associated pulmonary aspergillosis with posaconazole in this population. Methods In this observational sub‐stu…
View article: Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis Open
Monitoring and targeting a secukinumab trough concentration of 39.1 mg/L may be a viable treatment option in suboptimal responders. In patients with higher BMI, weight-based dosing may be needed in order to prevent underdosing.
View article: Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies Open
Background and Aims Although subcutaneous formulations of infliximab CT-P13 and vedolizumab are registered for treating moderate-to-severe inflammatory bowel disease [IBD], many questions on their use remain unanswered. We set up a multi-s…
View article: P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases
P533 Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseases Open
Background Infliximab (IFX) de-escalation (i.e., extending the dosing interval and/or decreasing the dose) has been attempted in patients with inflammatory bowel disease (IBD) who sustained treatment response following an earlier IFX escal…
View article: DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease
DOP89 Infliximab and ustekinumab clearance during induction predicts post-induction endoscopic outcomes in patients with Crohn’s Disease Open
Background Monitoring of monoclonal antibody clearance has been hypothesised to be an appealing approach for predicting treatment outcomes in patients with inflammatory bowel diseases. We aimed to investigate the benefits of monitoring inf…